AstraZeneca PLC (AZN)

33.95
0.05 0.15
NYSE : Health Care
Prev Close 33.90
Open 33.83
Day Low/High 33.82 / 34.12
52 Wk Low/High 25.55 / 35.04
Volume 4.38M
Avg Volume 4.40M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 86.14B
EPS 1.40
P/E Ratio 15.26
Div & Yield 1.90 (5.60%)

Latest News

Phase III ZONDA Trial For Benralizumab Shows Ability To Reduce Oral Steroid Use In Severe Asthma Patients

Phase III ZONDA Trial For Benralizumab Shows Ability To Reduce Oral Steroid Use In Severe Asthma Patients

Results from the Phase III ZONDA trial presented at the American Thoracic Society (ATS) 2017 International Congress demonstrated that adding benralizumab to standard of care allowed patients dependent on OCS to...

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.

GlaxoSmithKline Could Buy Out Partner Novartis

GlaxoSmithKline Could Buy Out Partner Novartis

Novartis holds a 36.5% stake in the healthcare company.

Wall Street Mixed as Rash of Weak Retail Earnings Continues

Wall Street Mixed as Rash of Weak Retail Earnings Continues

Wall Street hold mixed through to the close Friday after Nordstrom and J.C. Penney become the latest retail names to report on a weak quarter.

Closing Bell: GlobalStar Soars on Deal Considerations; Retail Sinks Wall Street Again

Closing Bell: GlobalStar Soars on Deal Considerations; Retail Sinks Wall Street Again

Stocks end the session mixed after Nordstrom and J.C. Penney become the latest retail names to report on a weak quarter.

S&P 500, Dow Decline After Retail Sales Rebound Buoys Rate-Hike Odds

S&P 500, Dow Decline After Retail Sales Rebound Buoys Rate-Hike Odds

Stocks held mostly lower on Friday as better-than-expected numbers on U.S. retail sales put a June rate hike on the markets' radar.

Stocks Hold Lower as Retail Sales, CPI Support June Rate Hike

Stocks Hold Lower as Retail Sales, CPI Support June Rate Hike

Stocks held lower on Friday even after better-than-expected numbers on U.S. retail sales and consumer prices.

Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration'

Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration'

GlaxoSmithKline shares traded firmly higher Friday after one of its biggest shareholders said he was dumping his holding after fifteen years out of "frustration".

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

U.S. stock futures are slipping Friday ahead of data on consumer prices and retail sales and after the U.S. and China reach a trade deal.

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Keytruda is now the only PD-1 or PD-L1 checkpoint inhibitor approved to treat first-line lung cancer either as monotherapy or as part of a combination therapy.

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche, the Swiss drugmaker, was let down by Tecentriq in clinical trials providing scope for Astra to close the gap and a possible boost for Bristol on Wednesday

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

Some investors are disappointed with the timing of Clovis' ovarian cancer maintenance clinical trial.

Earnings and Economics Push European Benchmarks Higher

Earnings and Economics Push European Benchmarks Higher

Markets shrugged off weak industrial data from China to focus on economics and earnings news closer to home

Astrazeneca Shares Gain After FDA Approves 'Durvalumab' Bladder Cancer Treatment

Astrazeneca Shares Gain After FDA Approves 'Durvalumab' Bladder Cancer Treatment

AstraZeneca shares edged higher Tuesday after it passed another key milestone in its pivot toward an oncology focused portfolio.

AstraZeneca's IMFINZI™ (durvalumab) Receives US FDA Accelerated Approval For Previously Treated Patients With Advanced Bladder Cancer

AstraZeneca's IMFINZI™ (durvalumab) Receives US FDA Accelerated Approval For Previously Treated Patients With Advanced Bladder Cancer

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to IMFINZI™ (durvalumab).

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

AstraZeneca Tops Earnings Estimate, but Crestor and Onglyza Sales Slow

AstraZeneca Tops Earnings Estimate, but Crestor and Onglyza Sales Slow

AstraZeneca posted stronger-than-expected first quarter earnings and held on to its full-year profit and revenue guidance despite a slowing in sales for some of its key treatments.

What to Expect From European Pharmaceuticals' First Quarter Results

What to Expect From European Pharmaceuticals' First Quarter Results

New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.

Europe Benchmarks Pare Losses but Caution Remains

Europe Benchmarks Pare Losses but Caution Remains

French and Spanish Stocks were back in the black at noon, leading a partial reversal of earlier losses for the continent as a whole

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

TAGRISSO® (osimertinib) Receives US FDA Full Approval

TAGRISSO® (osimertinib) Receives US FDA Full Approval

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for TAGRISSO ® (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth...

Astrazeneca Scores Milestone Victory in Oncology

Astrazeneca Scores Milestone Victory in Oncology

A double victory in oncology failed to lift Astra stock, amid broad weakness in European markets

Keep Trading AstraZeneca From the Long Side

Keep Trading AstraZeneca From the Long Side

The stock is headed toward a bullish golden cross.

New Data Demonstrate RSV Immunoprophylaxis With SYNAGIS® (palivizumab) May Result In Reduced Overall Costs In Preterm Infants Born At 29-32 WGA Who Are Less Than Three Months Of Age

New Data Demonstrate RSV Immunoprophylaxis With SYNAGIS® (palivizumab) May Result In Reduced Overall Costs In Preterm Infants Born At 29-32 WGA Who Are Less Than Three Months Of Age

AstraZeneca today announced new results data which evaluated the cost-effectiveness of SYNAGIS ® (palivizumab) for respiratory syncytial virus (RSV) in preterm infants 29-34 weeks gestational age compared to those...

AstraZeneca Shares Progress On LYNPARZA™ (olaparib) Tablets In The US

AstraZeneca Shares Progress On LYNPARZA™ (olaparib) Tablets In The US

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for LYNPARZA™ (olaparib) tablets (300mg twice daily) for use in platinum-sensitive,...

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.